Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease

Journal of Vascular Surgery

Volumn 60, Issue 4, 2014, Pages 993-1001

  Guo, Baolei ^a   Tan, Qiwen ^a   Guo, Daqiao ^a   Shi, Zhenyu ^a   Zhang, Chunyan ^a   Guo, Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DNA; TICLOPIDINE;

AGED; ALLELE; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOPPLER ECHOGRAPHY; DRUG RESPONSE; ENDOVASCULAR SURGERY; FEMALE; FEMORAL ARTERY; FOLLOW UP; GENOTYPE; GRAFT PATENCY; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; LOSS OF FUNCTION MUTATION; MALE; NITINOL STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOGENETICS; PLATELET REACTIVITY; PROGNOSIS; RISK ASSESSMENT; SELF EXPANDING STENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; ANALOGS AND DERIVATIVES; ARTERIOSCLEROSIS OBLITERANS; COMPUTER ASSISTED TOMOGRAPHY; GENETIC POLYMORPHISM; GENETICS; GRAFT OCCLUSION, VASCULAR; LEG; METABOLISM; PROSPECTIVE STUDY; PROSTHESIS FAILURE; STENT; SURGERY; VASCULARIZATION;

AGED; ALLELES; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANKLE BRACHIAL INDEX; ARTERIOSCLEROSIS OBLITERANS; CYTOCHROME P-450 CYP2C19; DNA; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GENOTYPE; GRAFT OCCLUSION, VASCULAR; HUMANS; LEG; MALE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; STENTS; TICLOPIDINE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84908253917     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2014.03.293     Document Type: Article

References (26)

1. M. Gent, D. Beaumont, J. Blanchard, M.G. Bousser, J. Coffman, and J.D. Easton A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
2. P.P. Cacoub, D.L. Bhatt, P.G. Steg, E.J. Topol, M.A. Creager CHARISMA Investigators Patients with peripheral arterial disease in the CHARISMA trial Eur Heart J 30 2009 192 201
3. M.T. Allemang, R.R. Rajani, P.R. Nelson, A. Hingorani, and V.S. Kashyap Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures Ann Vasc Surg 27 2013 62 67
4. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol 56 2010 321 341
5. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
6. K.P. Bliden, J. DiChiara, U.S. Tantry, A.K. Bassi, S.K. Chaganti, and P.A. Gurbel Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
7. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
8. S.A. Scott, K. Sangkuhl, C.M. Stein, J.S. Hulot, J.L. Mega, and D.M. Roden Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update Clin Pharmacol Ther 94 2013 317 323
9. S.R. Steinhubl Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines Circulation 121 2010 481 483
10. N.A. Farid, A. Kurihara, and S.A. Wrighton Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 2010 126 142
11. K.M. Momary, M.P. Dorsch, and E.R. Bates Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy 30 2010 265 274
12. D.M. Roden, and A.R. Shuldiner Responding to the clopidogrel warning by the US Food and Drug Administration: real life is complicated Circulation 122 2010 445 448
13. G.E. Rivard, K.E. Brummel-Ziedins, K.G. Mann, L. Fan, A. Hofer, and E. Cohen Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography J Thromb Haemost 3 2005 2039 2043
14. H. Wu, J. Qian, A. Sun, Q. Wang, and J. Ge Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment Circ J 76 2012 2773 2778
15. D.J. Angiolillo, S. Suryadevara, P. Capranzano, M.Z. Zenni, L.A. Guzman, and T.A. Bass Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists Catheter Cardiovasc Interv 1 2009 1 14
16. M. Bosiers, K. Deloose, K. Keirs, J. Verbist, and P. Peeters Prevention and treatment of in-stent restenosis J Cardiovasc Surg 51 2010 591 598
17. A.R. Shuldine, M.R. Vesely, and A. Fisch CYP2C19 genotype and cardiovascular events JAMA 307 2012 1482 1485
18. T. Geisler, H. Langer, M. Wydymus, K. Göhring, C. Zürn, and B. Bigalke Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
19. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
20. S.C. Beinart, P. Kolm, E. Veledar, Z. Zhang, E.M. Mahoney, and O. Bouin Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial J Am Coll Cardiol 46 2005 761 769
21. G. Cayla, J.S. Hulot, S.A. O'Connor, A. Pathak, S.A. Scott, and Y. Gruel Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis JAMA 306 2011 1765 1774
22. A. Planas, A. Clará, J. Marrugat, J.M. Pou, A. Gasol, and A. de Moner Age at onset of smoking is an independent risk factor in peripheral artery disease development J Vasc Surg 35 2002 506 509
23. W. Hochholzer, D. Trenk, J.L. Mega, T. Morath, C. Stratz, and C.M. Valina Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy Am Heart J 162 2011 518 526.e5
24. P.A. Gurbel, K.P. Bliden, D.K. Logan, D.J. Kereiakes, K.C. Lasseter, and A. White The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study J Am Coll Cardiol 62 2013 505 512
25. M.C. Wesley, F.X. McGowan, R.A. Castro, S. Dissanayake, D. Zurakowski, and J.A. DiNardo The effect of milrinone on platelet activation as determined by TEG platelet mapping Anesth Analg 108 2009 1425 1429
26. E.H. Madsen, J. Saw, S.R. Kristensen, E.B. Schmidt, C. Pittendreigh, and E. Maurer-Spurej Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, verify now, and thrombelastography in patients undergoing percutaneous coronary intervention Clin Chem 56 2010 839 847